Mishra Vijay, Nayak Pallavi, Sharma Mayank, Albutti Aqel, Alwashmi Ameen S S, Aljasir Mohammad Abdullah, Alsowayeh Noorah, Tambuwala Murtaza M
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
Faculty of Pharmaceutical Sciences, PCTE Group of Institutes, Ludhiana 142021, Punjab, India.
Pharmaceutics. 2021 Sep 27;13(10):1568. doi: 10.3390/pharmaceutics13101568.
The occurrence of diabetes mellitus (DM) is increasing rapidly at an accelerating rate worldwide. The status of diabetes has changed over the last three generations; whereas before it was deemed a minor disease of older people but currently it is now one of the leading causes of morbidity and mortality among middle-aged and young people. High blood glucose-mediated functional loss, insulin sensitivity, and insulin deficiency lead to chronic disorders such as Type 1 and Type 2 DM. Traditional treatments of DM, such as insulin sensitization and insulin secretion cause undesirable side effects, leading to patient incompliance and lack of treatment. Nanotechnology in diabetes studies has encouraged the development of new modalities for measuring glucose and supplying insulin that hold the potential to improve the quality of life of diabetics. Other therapies, such as β-cells regeneration and gene therapy, in addition to insulin and oral hypoglycemic drugs, are currently used to control diabetes. The present review highlights the nanocarrier-based drug delivery systems and emerging treatment strategies of DM.
糖尿病(DM)在全球范围内正以加速的速度迅速增加。在过去三代人的时间里,糖尿病的状况已经发生了变化;以前它被认为是老年人的一种小疾病,但目前它已成为中青年发病和死亡的主要原因之一。高血糖介导的功能丧失、胰岛素敏感性和胰岛素缺乏会导致1型和2型糖尿病等慢性疾病。糖尿病的传统治疗方法,如胰岛素增敏和胰岛素分泌,会产生不良副作用,导致患者依从性差和治疗不足。糖尿病研究中的纳米技术促进了测量葡萄糖和供应胰岛素的新方法的发展,这些方法有可能改善糖尿病患者的生活质量。除了胰岛素和口服降糖药之外,目前还使用其他疗法,如β细胞再生和基因疗法来控制糖尿病。本综述重点介绍了基于纳米载体的药物递送系统和糖尿病的新兴治疗策略。